ProKidney Engages in Major Healthcare Conferences
WINSTON-SALEM, N.C. – ProKidney Corp. (Nasdaq: PROK), a pioneering biotechnology company focused on innovative cell therapy for chronic kidney disease (CKD), is poised to make a significant impact at two prominent healthcare conferences this month. Senior executives from ProKidney will represent the company at the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference.
Details of the Events
Guggenheim Inaugural Healthcare Innovation Conference
This exciting event takes place in Boston, where ProKidney will participate in a fireside chat on November 13, 2024, at 10:30 AM ET. This format allows for an intimate discussion, providing attendees with insights into ProKidney’s innovative approaches and future directions.
Jefferies London Healthcare Conference
Following the Guggenheim conference, ProKidney will attend the Jefferies London Healthcare Conference on November 20, 2024, at 10:00 AM GMT, featuring another fireside chat format. This event provides further opportunities for ProKidney to engage with investors and industry experts, showcasing their revolutionary work in kidney health.
Accessing Live Webcasts and Replays
Both conferences will feature live webcasts, accessible through the “Events” section of ProKidney’s website. After the conferences conclude, replays will be available for up to 90 days, ensuring that interested parties can catch up on the discussions and insights shared during these sessions.
One-on-One Meetings with Management
In addition to the group discussions at these conferences, ProKidney’s management team is eager to host one-on-one meetings with interested investors. These personalized discussions will allow for deeper engagement and tailored conversations about ProKidney’s strategic vision and advancements.
About ProKidney Corp.
Founded in 2015, ProKidney is on a mission to transform the treatment landscape for chronic kidney disease. Their lead candidate, rilparencel, is an innovative and patented cellular therapy currently undergoing Phase 2 and Phase 3 clinical studies. This groundbreaking therapy aims to preserve kidney function in patients with diabetes who are at high risk of kidney failure. With the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, rilparencel is positioned to make significant strides in patient care.
Get Involved with ProKidney
For more information regarding ProKidney’s initiatives and their upcoming conferences, interested parties should visit ProKidney’s website. The site provides a wealth of information about their innovative therapeutic solutions and ongoing clinical trials.
Frequently Asked Questions
What are the significance of the upcoming conferences for ProKidney?
The conferences provide ProKidney with a platform to showcase their innovations and engage directly with investors and experts in the healthcare field.
How can I access the live webcasts of these conferences?
The live webcasts will be available on ProKidney’s website under the “Events” section.
What is rilparencel?
Rilparencel is ProKidney’s lead product candidate, a patented cellular therapy aimed at preserving kidney function in individuals at high risk of kidney failure.
When will ProKidney's management be available for one-on-one meetings?
Management will be available during both conferences, and interested investors should contact their respective conference representatives to arrange these meetings.
What designations has rilparencel received?
Rilparencel has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential in improving patient outcomes.
